AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04623502 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 13C-Fructose
Description: Patients in the 13C-fructose arm will receive an infusion of a 13C-fructose solution. In most cases, the fructose infusion will be administered for 2-3 hours prior to resection of the mass. During the surgical procedure, 2-4mL of blood will be obtained approximately every 30 minutes to monitor blood glucose and/or blood pH. The infusion will be stopped after resection.
Study NCT05829200 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Transcranial Doppler (TCD)
Description: All individuals who are consented for elective or urgent carotid endarterectomy would be eligible to participate. If patient gives consent, they would undergo an approximately 30-60 minute TCD study. We will collect the number of high intensity transient signals (HITS). The patient would undergo surgery regardless of the TCD result.
Study NCT04954170 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: IRRTM
Description: IRRT at maximal 90° abduction and maximal external rotation is performed with the shoulder at maximal 90° rotation and the elbow flexed to 90° (Fig. 2). The patient is then asked to resist the external rotation force applied perpendicular to the forearm by the investigator. The test is considered positive if the patient could not hold the position or if he or she showed weakness of resisted internal rotation compared with the other side. It should be noted the maximal 90° abduction and maximal external rotation is active range of motion. Passive motion may affect the result of the test because of severe pain.
Study NCT04954170 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: the lift-off test
Description: The lift-off test is performed by placing the hand of the affected arm on the back (at the position of the midlumbar spine) and asking the patient to internally rotate the arm to lift the hand off the back \[9\]. The test is considered positive if the patient is unable to lift the arm posteriorly off the back or if he or she performs the lifting manoeuvre by extending the elbow or the shoulder. Weakness is also as a positive result.
Study NCT04954170 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: the belly-press test
Description: The belly-press test is performed with the arm at the side and the elbow flexed to 90°, by having the patient press the palm into his or her abdomen by internally rotating the shoulder \[3, 5\]. The test is considered positive (1) if the patient shows a weakness in comparison with the opposite shoulder or (2) the patient pushes the hand against the belly by wrist flexion, despite instruction to the contrary.
Study NCT03156452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: 500 mg and 250mg tablets for oral administration
Study NCT03156452 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: 5mg tablets for oral administration
Study NCT04501445 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Written Summary of Rounds
Description: The summary was organized as follows for each of the most important ICU problems: 1) Description of the problem, 2) Ways the ICU team is addressing the problem i.e. consultations, diagnostic tests, and treatments. 3) An assessment of whether the problem is improving or worsening.
Study NCT00597909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium phenylacetate and sodium benzoate injection 10% / 10%
Description: 5.5 g/m² diluted in 10% dextrose, IV as a 2-hour loading (initial) dose, followed by the same dose over 24 hours (maintenance infusion); maintenance infusion will be continued for 3 days (70 hours)
Study NCT00597909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium phenylacetate and sodium benzoate injection 10% / 10%
Description: 2.75 g/m² diluted in 10% dextrose, IV as a 2-hour loading (initial) dose, followed by the same dose over 24 hours (maintenance infusion); maintenance infusion will be continued for 3 days (70 hours)
Study NCT00597909 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo solution (10% dextrose)
Description: Placebo solution (10% dextrose), IV as a 2-hour loading (initial) dose, followed by the same dose over 24 hours (maintenance infusion); maintenance infusion will be continued for 3 days (70 hours)
Study NCT01091532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UK-396,082
Description: 100mg given orally twice daily for 14 days~The decision to proceed to the next higher dose will be made jointly by the Pfizer Study Team and the Investigator after careful review of available safety, tolerability and PK information from previous cohorts and dosing periods. The doses will be selected such that the predicted Cmax will not exceed 2.95 mcg/mL and/or the predicted increase in exposure will not exceed 3.5-fold that of the previously studied dose.
Study NCT01091532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: given orally twice daily for 14 days
Study NCT01091532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UK-396,082
Description: 300mg given orally twice daily for 14 days~The decision to proceed to the next higher dose will be made jointly by the Pfizer Study Team and the Investigator after careful review of available safety, tolerability and PK information from previous cohorts and dosing periods. The doses will be selected such that the predicted Cmax will not exceed 2.95 mcg/mL and/or the predicted increase in exposure will not exceed 3.5-fold that of the previously studied dose.
Study NCT01091532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UK-396,082
Description: 1000mg given orally twice daily for 14 days~The decision to proceed to the next higher dose will be made jointly by the Pfizer Study Team and the Investigator after careful review of available safety, tolerability and PK information from previous cohorts and dosing periods. The doses will be selected such that the predicted Cmax will not exceed 2.95 mcg/mL and/or the predicted increase in exposure will not exceed 3.5-fold that of the previously studied dose.
Study NCT01091532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UK-396,082
Description: UK-396,082 given orally, once on Days 1 \& 14, and twice daily on Days 3-13.~The decision to proceed to the next higher dose will be made jointly by the Study Team and the Investigator after careful review of available safety, tolerability and PK information from previous cohorts. Dependent on the emerging safety, tolerability and PK data, Cohort 4 may be recruited to study a higher (or lower) dose of UK-396,082 in order to characterize further the safety, toleration and PK and/or to define the maximum tolerated dose. The dose in Cohort 4 will be selected such that the predicted Cmax will not exceed 46 mcg/mL and/or the predicted increase in exposure will not exceed 3.5-fold that of the previously studied dose.
Study NCT01091532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: given orally, once on Days 1 \& 14, and twice daily on Days 3-13.
Study NCT01935154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vx-001
Study NCT01935154 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03969758 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprofloxacin
Description: will receive tablet Ciprofloxacin (500 mg BDS) and tablet Metronidazole (800 mg TDS) for 2 weeks orally. Percutaneous aspiration or drainage of the liver abscess will be done when there is enough liquid content/pus amenable for aspiration or drainage. Percutaneous drainage or aspiration will be done in liver abscess with size of ≥ 5 cm and \<5 cm respectively.
Study NCT03969758 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefixime
Description: will receive tablet Cefixime (200 mg BDS) and tablet Metronidazole (800 mg TDS) for 2 weeks orally. Percutaneous aspiration or drainage of the liver abscess will be done when there is enough liquid content/pus amenable for aspiration or drainage. Percutaneous drainage or aspiration will be done in liver abscess with size of ≥ 5 cm and \<5 cm respectively.
Study NCT00655798 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: plain yogurt and capsules containing cellulose
Study NCT00655798 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Plain Yogurt + mix of anti-oxidants capsules
Description: plain yogurt and capsules containing mix of anti-oxidants
Study NCT00655798 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Yogurt containing Lactobacillus helveticus
Description: Yogurt containing the probiotic Lactobacillus helveticus
Study NCT02081469 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: TDF
Description: To compare extend TDF 24 wks versus 48 wks prophylaxis efficacy in chemotherapy CHB patients
Study NCT00984230 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: BSF
Description: feeding amount according to individual baby need
Study NCT00984230 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BSF + Lactoferrin + Probiotics
Description: feeding amount according to individual baby need
Study NCT00984230 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BSF + Lactoferrin + Probiotics + OS
Description: feeding amount according to individual baby need
Study NCT02334969 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naoxintong Capsule
Description: This is Naoxintong capsule,which is composed of Huangqi,Chishao,Danshen,Danggui, Chuanxiong,Taoren,Honghua,Ruxiang,Moyao,Jixueteng,Niuxi,Guizhi,Sangzhi,Dilong,Quanxie,etal.
Study NCT04954170 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: the IRLS test
Description: IRLS test is evaluated with the affected arm of the patient was held by the examiner at maximum internal rotation \[10\]. The back of the hand is then passively lifted away from the body until almost full internal rotation is reached. Then, the patient is asked to actively maintain this position. The test is considered positive when the patient fails to maintain the position and the hand lagged.
Study NCT04954170 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: the bear-hug test
Description: The bear-hug test is performed with the palm of one side placed on the opposite shoulder and fingers extended and the elbow positioned anterior to the body \[3\]. The patient is then asked to hold that position when the examiner tried to pull the patient's hand from the shoulder with an external rotation force applied perpendicular to the forearm. The test is considered positive if the patient could not hold the hand against the shoulder or if he or she showed weakness compared with the other side.
Study NCT04954170 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: IRRT 0°
Description: IRRT at 0° abduction and 0° external rotation is performed with the arm at the side and the elbow flexed to 90° (Fig. 1). The patient is then asked to resist the external rotation force applied by the investigator. The test is considered positive if the patient could not hold the position at the side or if he or she showed weakness of resisted internal rotation compared with the other side. The test is negative if patients only complain of pain.
Study NCT04954170 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic arthroscopy
Description: At the time of surgery, general anaesthesia was administered and the patient was placed in beach-chair position. A complete arthroscopic exploration of the glenohumeral joint and the subacromial space was performed through a standard posterior portal. The senior author performed a complete arthroscopic exploration. Arthroscopic evaluation of the rotator cuff was considered the gold standard for making the definitive diagnosis. Evaluation of the SSC was carried out with both a 30° arthroscope and a 70° arthroscope.
Study NCT01444677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MB12066
Description: MB12066 300mg
Study NCT01444677 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MB12066
Description: MB12066 400mg
Study NCT01444677 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MB12066
Description: MB12066 100mg
Study NCT01444677 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MB12066
Description: MB12066 200mg
Study NCT01444677 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 300mg (single dose), 400mg (single dose), 100mg (multiple dose), 200mg (multiple dose)
Study NCT02820701 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: OMT
Description: Osteopathic Manipulative Treatment to low back region
Study NCT01043900 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: repetitive transcranial magnetic stimulation (rTMS)
Description: 30 daily sessions: each with 40 trains of 5 seconds at 10Hz, with a 25 second inter-train interval, at an intensity of 110% of motor threshold. Site: Right Dorsolateral Prefrontal Cortex
Study NCT01043900 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: repetitive transcranial magnetic stimulation (rTMS)
Description: 30 daily sessions: each with 40 trains of 5 seconds at 10Hz, with a 25 second inter-train interval, at an intensity of 110% of motor threshold. Site: Right Dorsolateral Prefrontal Cortex
Study NCT02334969 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: placebo capsule has the same as Naoxintong capsule in the appearance, shape,colour and content tinct.
Study NCT03138915 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HVPG measurement
Description: HVPG obtained by means of catheterization of a hepatic vein with a balloon catheter.
Study NCT03138915 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CTA
Description: Radiomic features were extracted from CTA images.
Study NCT02262130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omalizumab
Study NCT01419171 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OMEGA™ Monorail Coronary Stent System
Description: All enrolled patients are treated with the OMEGA™ Monorail Bare Metal Coronary Stent System and followed for 12 months post-procedure.
Study NCT01919372 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telemedic assistance with a technological system
Study NCT01919372 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Study NCT04118361 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: HINTS Test
Description: The HINTS test is a clinical test composed of 3 oculomotor examinations:~* Search for high-frequency vestibulo-ocular reflex during a passive head impulse test~* Highlighting of spontaneous nystagmus: it must be sought without, then with Frenzel glasses because they allow to temporarily interrupt the ocular fixation.~* Vertical divergence~This test is performed at the patient's bedside in about 3 minutes. Presence of at least one of the three items of central locator value is sufficient to diagnose a central cause of VAS, including normal early brain imaging.
Study NCT04118361 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: STANDING Algorithm
Description: The STANDING algorithm consists of clinical elements that can be evaluated in about 10 minutes at the patient's bedside: two oculomotor examinations (Head Impulse Test and detection of a nystagmus), detection of ataxia and the practice of release maneuvers.
Study NCT04674137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XC8 100 mg
Description: 1 tablet of XC8 100 mg once daily in the morning during 12 weeks of treatment period.
Study NCT04674137 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tablet of placebo once daily in the morning during 12 weeks of treatment period.
Study NCT01868269 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dexamethasone acetate
Description: First step:~immunosuppressive treatment with dexamethasone
Study NCT01868269 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: dexamethasone and cyclophosphamide
Description: second step (in case of insufficient response): immunosuppressive treatment with dexamethasone and cyclophosphamide
Study NCT01868269 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: dexamethasone and rituximab
Description: third step (in case of insufficient response): immunosuppressive treatment with dexamethasone and rituximab
Study NCT03709433 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACT groups and mobile app
Description: See arm description.
Study NCT04024228 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard-Dose influenza virus surface antigens (haemagglutinin and neuraminidase), Inactivated, Influenza Vaccine Quadrivalent, 2019-2020 Northern Hemisphere Strains (QIV-SD)
Description: Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: IM
Study NCT04024228 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High-Dose Influenza Vaccine (split virion, inactivated), Quadrivalent (QIV-HD) 2019-2020 Northern Hemisphere formulation
Description: Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: IM
Study NCT01620996 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Minimal Intervention
Description: There is no clear definition of this term and it has been used by many different groups to refer to attempts to alter behavior by providing very brief, focused interventions. A slightly more developed model guiding intervention is called the 5-A model. This refers to the acronym Ask, Advise, Assess, Assist and Arrange. This model has been endorsed by the US Public Health Department, who has incorporated the 5-A approach into their clinical practice guidelines (A Clinical Practice Guideline for Treating Tobacco Use and Dependence; A US Public Health Service Report. JAMA, June 20, 2000 - Vol 283 No. 24; see also http://www.surgeongeneral.gov/tobacco/tobaqrg.htm).
Study NCT01620996 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivational Interviewing
Description: Motivational Interviewing has its roots in alcohol abuse counseling and was pioneered by Miller and Rollnick. It is an approach to counseling that is geared toward increasing an individual's motivation, or buy-in, to the work that needs to be done to reduce substance dependence. Miller and Rollnick offer the approach as a brief intervention (hence some confusion with the term minimal intervention) guided by the following mediators of change, which they call ingredients of change, summarized by the Acronym FRAMES:~FEEDBACK of personal risk or impairment Emphasis on personal RESPONSIBILITY for change Clear ADVICE to change A MENU of alternative change options Therapist EMPATHY Facilitation of client SELF-EFFICACY or optimism~These mediators/ingredients are delivered by the clinician using the following principles:~Express Empathy Develop Discrepancy Avoid Argumentation Roll with Resistance Support Self-Efficacy
Study NCT01620996 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivational Enhancement
Description: Motivational enhancement is the most comprehensive term and reflects the integration of two major theorists; Millner and Rollnick on the one hand, and Prochaska and his colleagues on the other. The work of Miller and Rollnick occurred within substance abuse, primarily alcohol abuse and is best summarized in the section above on motivational interviewing. As Prochaska's work, which initially began in the area of smoking cessation but quickly expanded to include wide-ranging health behaviours, developed Miller and Rollnick incorporated his work with theirs.Prochaska's model derives from his long term study of the process of behaviour change regardless of the model of intervention implemented.The model is often referred to as the stages of change model, or readiness to change model.~The stages of change model identifies five separate stages; precontemplation,contemplation, preparation, action, and maintenance~These stages are specific to different behaviours.
Study NCT03491189 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lag screw fixation
Description: surgical fixation
Study NCT01105351 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: folic acid plus B6 and B12
Description: folic acid 400 µg plus vitamin B12 plus B6
Study NCT01105351 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: folic acid
Description: folic acid 400 µg
Study NCT02477098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: preoperative 0.5% ropivacaine hydrochloride preoperative
Description: Before surgery (Pre RSB) , a bilateral RSB with ropivacaine hydrochloride will be performed under ultrasound guidance by one anaesthesiologist.At the end of surgery, a bilateral RSB with saline will be performed under ultrasound guidance by one anaesthesiologist.
Study NCT02477098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: postoperative 0.5% Ropivacaine hydrochloride
Description: Before surgery, a bilateral RSB with saline will be performed under ultrasound guidance by one anaesthesiologist.At the end of surgery, a bilateral RSB with ropivacaine hydrochloride will be performed under ultrasound guidance by one anaesthesiologist.
Study NCT00163137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lasofoxifene
Description: lasofoxifene 0.25mg
Study NCT00163137 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: raloxifene
Description: raloxifene 60 mg/day
Study NCT00163137 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0 mg/day
Study NCT01252329 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: elective lymph node dissection
Description: This entails selective lymph node dissection in patients with negative lymph node exams. The nodes dissected are those that drain from the high risk cutaneous squamous cell cancer. Subsequent radiation and/or chemotherapy may be administered in a small percentage of subjects, depending on the result of the neck dissection.